Core Insights - The company announced a cash dividend of 10 yuan per 10 shares, totaling 78.3072 million yuan, which represents 59.32% of the net profit attributable to shareholders for the first half of 2025 [1] - Since its IPO in 2021, the company has distributed a total of 1.28 billion yuan in cash dividends, which is approximately 70% of the funds raised during the IPO, reflecting its commitment to shareholder returns [1] - The company has implemented two share buyback programs, repurchasing 2.066 million shares, accounting for 2.61% of the total share capital, with a total investment exceeding 175 million yuan [1] Financial Performance - In the first half of 2025, the company achieved a revenue of 430 million yuan, representing a year-on-year growth of 8.41% [2] - The net profit attributable to shareholders for the same period was 132 million yuan, showing a year-on-year increase of 6.57% [2] R&D and Market Strategy - The company invested 48.1957 million yuan in R&D in the first half of 2025, which is 11.21% of its sales [2] - During the reporting period, the company launched 140 new products and obtained 23 new patents/software copyrights, along with 203 new medical device certifications [2] - The company is focusing on a global strategy, participating in various domestic and international exhibitions to enhance brand influence and market competitiveness, with products exported to over 170 countries and regions [2] Future Plans - The company has developed a "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan for 2025, which includes measures to focus on core operations, advance fundraising project construction, strengthen investor communication, and emphasize shareholder returns [2] - The plan aims to fulfill the responsibilities of a listed company through strong performance, sound corporate governance, and active investor returns, thereby maintaining market image and promoting stable operations in the Sci-Tech Innovation Board [2]

Group 1 - The core point of the announcement is the approval of the 2025 interim profit distribution plan by the supervisory board, which is deemed beneficial for the company's sustainable development and aligns with legal regulations [3][12]. - The supervisory board meeting was held on September 18, 2025, with all three attending supervisors agreeing to waive the notice period requirements, confirming the legality and validity of the meeting [2][4]. - The profit distribution plan involves a cash dividend of 10 yuan (including tax) for every 10 shares, with no stock bonus or capital increase [7][10]. Group 2 - The total distributable profit available to the parent company as of June 30, 2025, is approximately 1.65 billion yuan, and the proposed cash dividend distribution totals approximately 78.31 million yuan, representing 59.32% of the net profit attributable to shareholders for the first half of 2025 [8][11]. - The distribution will be based on the total share capital after deducting shares held in the company's repurchase account, which amounts to 973,631 shares [8][9]. - The profit distribution plan does not require submission to the shareholders' meeting for approval, as it falls under the authority granted by the shareholders at the 2024 annual meeting [10][11].

杭州奥泰生物技术股份有限公司（以下简称"公司"）第三届监事会第十六 次会议（以下简称"本次会议"）于 2025 年 9 月 18 日上午 9：00 在公司会议室 以现场会议的方式召开。公司全体监事均同意豁免本次监事会会议通知时限要 求。会议应出席监事 3 名，实际出席监事 3 名。本次会议的召集、召开程序和 方式符合《中华人民共和国公司法》等法律法规以及《杭州奥泰生物技术股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况： 会议由监事会主席高跃灿先生主持召开，全体与会监事经认真审议和表决， 形成以下决议： 审议通过《关于<2025 年中期利润分配方案>的议案》 证券代码：688606 证券简称：奥泰生物 公告编号：2025-041 杭州奥泰生物技术股份有限公司 第三届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况： 议案表决情况：本议案有效表决票 3 票，同意 3 票、反对 0 票、弃权 0 票。 根据 2024 年年度股 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-042 杭州奥泰生物技术股份有限公司 2025 年中期利润分配方案公告 购专用证券账户中股份为基数分配利润。本次利润分配方案如下： 公司拟向全体股东每10股派发现金红利10元（含税）。截至本公告披露日， 公司总股本79,280,855股，扣减回购专用证券账户中股份数973,631股后参与分 配股数共78,307,224股，以此计算合计拟派发现金红利78,307,224.00元（含税）， 占2025年上半年度合并报表归属于上市公司股东净利润的比例59.32%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配比例：每 10 股派发现金红利 10 元（含税），不转增股本，不送红 股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减杭州奥泰 生物技术股份有限公司（以下简称"公司"）回购专用证券账户中股份为基数， 具体日期将在权益分派实施公告中明确。 实施权益分派的股权登记日前公司应分配股数（总股本扣减公司回购 专用证券账户股份余额）发生变动的， ...

Group 1 - The company, Aotai Biologics (688606.SH), announced a profit distribution plan for the mid-2025 period, proposing a cash dividend of 10 yuan (before tax) for every 10 shares [1]

Core Viewpoint - Hangzhou Aotai Biotechnology Co., Ltd. announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 10 yuan per 10 shares to all shareholders, which will not include stock increases or bonus shares [1] Summary by Relevant Sections - **Dividend Distribution** - The company plans to distribute a total cash dividend of 78,307,224 yuan (including tax), based on a total share capital of 79,280,855 shares, with 78,307,224 shares eligible for distribution after deducting shares held in the repurchase account [1] - **Profit Allocation** - The proposed cash dividend represents 59.32% of the net profit for the first half of 2025 [1] - **Approval and Impact** - The distribution plan has been approved by the board of directors and the supervisory board, and it does not require submission to the shareholders' meeting for approval based on the authorization from the 2024 annual shareholders' meeting. Additionally, it is stated that this plan will not have a significant impact on the company's operating cash flow [1]

Core Viewpoint - Aotai Biologics announced the completion of the stock registration for its 2022 restricted stock incentive plan, marking a significant step in its employee incentive strategy [2] Group 1 - The company received a confirmation letter from the Shanghai branch of China Securities Depository and Clearing Corporation on September 12, 2025 [2] - The number of shares vested in this phase is 438,890 shares [2] - The shares were sourced from the company's repurchase of its A-share common stock in the secondary market [2]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-040 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，杭州奥泰生物技术股份有限公司（以下 简称"公司"）于 2025 年 9 月 12 日收到中国证券登记结算有限责任公司上海分 公司出具的《过户登记确认书》，完成了公司 2022 年限制性股票激励计划（以 下简称"本次激励计划"）首次授予第三个归属期及预留授予第二个归属期归属 的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 杭州奥泰生物技术股份有限公司 关于 2022 年限制性股票激励计划首次授予第三个归 属期及预留授予第二个归属期归属结果的公告 （一）2022 年 6 月 27 日，公司召开第二届董事会第十五次会议，审议通过 了《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划（草案） 及其摘要>的议案》《关于<杭州奥泰生物技术股份 ...

Group 1 - The company, Aotai Biological, has nearly 100 animal/pet testing products and has been actively selling in international markets [1] - The company recognizes the significant potential of the domestic pet market and has begun to actively develop its business in this area [1]

Group 1 - The company is committed to delivering strong performance, maintaining good corporate governance, and providing positive returns to investors [1] - The company emphasizes its responsibility and obligations as a publicly listed entity, aiming to reward the trust of its investors [1]